Louis Vandermolen is an Oncology physician affiliated with University of Southern California. OpenAlex indexes 27 publications with 520 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
520 Superior Ave
Suite 300
Newport Beach, CA 926633637
Telephone
949-646-6441Provider last certified this registry record 14 Aug 2021.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Tempus AI, IncProgram year20251 payment
- PFIZER INC.Program year20232 payments
- Bayer Healthcare Pharmaceuticals Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
64.4%Aromatase Inhibitor43%Anastrozole90%Exemestane9%Letrozole2%Part D<11 patientsKinase inhibitor8.7%Ibrance53%Imatinib Mesylate20%Calquence14%Kisqali13%Part D<11 patients+ 6 more classes in this area
Blood & clotting
9.2%Factor Xa inhibitor6.5%Eliquis74%Xarelto27%Part D<11 patientsVitamin K antagonist2%Warfarin Sodium100%Part D<11 patients+ 1 more class in this area
Nervous system
9.2%Gabapentinoids2%Gabapentin100%Part D<11 patientsBenzodiazepine1.7%Lorazepam56%Alprazolam44%Part D<11 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Should High-Dose Interleukin-2 Still Be the Preferred Treatment for Patients with Metastatic Melanoma?
Cancer Biotherapy and Radiopharmaceuticals
2012 - Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?
Cancer Biotherapy and Radiopharmaceuticals
2011
Similar KOLs
Other experts from the same institution or the same specialty.
David Liebeskind, MD
University of Southern California
Lon Schneider, MD
University of Southern California
Amytis Towfighi, MD
University of Southern California
Norah Terrault, MD
University of Southern California
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”